Patent intelligence · US
US 6461870
13C glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control
13C glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control
Patent details — US 6461870
- Jurisdiction
- US
- Status
- expired
- Grant date
- Oct 8, 2002
- Expiration
- Oct 3, 2022
- Applicant
- Isotechnika, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K51/1206
Quick answer
US 6461870 (13C glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control) is held by Isotechnika, Inc.. Status: expired. Granted Oct 8, 2002. Expires Oct 3, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Isotechnika, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K51/1206
More from Isotechnika, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12415779
Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof
granted -
US 12391642
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12331026
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
granted -
US 12264167
Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors
granted -
US 12171741
2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted -
US 12077506
Indane derivatives as hypoxia inducible factor-2(α) inhibitors
granted -
US 11939303
Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives
granted -
US 11753366
Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors
granted
Frequently asked questions
What is US patent 6461870?
US 6461870 (13C glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control) is held by Isotechnika, Inc.. Status: expired. Granted Oct 8, 2002. Expires Oct 3, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6461870?
Isotechnika, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 6461870 expire?
Our index shows an expiration date of Oct 3, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.